XNYS
WST
Market cap25bUSD
Oct 08, Last price
363.27USD
1D
-0.88%
1Q
2.70%
Jan 2017
328.23%
Name
West Pharmaceutical Services Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Related entities
Subsidiaries (6)
WEST PHARMA. SERVICES IL, LTD.
WEST PHARMACEUTICAL SERVICES HOLDING GMBH
WEST PHARMACEUTICAL SERVICES SINGAPORE PTE. LTD.
TGPR HOLDINGS LIMITED
WEST PHARMACEUTICAL PACKAGING INDIA PRIVATE LIMITED
WEST PHARMACEUTICAL SERVICES DEUTSCHLAND GMBH & CO. KG
Key people
Non-Independent Chairman of the Board, President, Chief Executive Officer · since 2022
Shane Campbell
Senior Vice President, Chief Proprietary Segment Officer · since 2025
Annette Favorite
Chief Human Resources Officer, Senior Vice President · since 2015
Senior Vice President, General Counsel, Corporate Secretary · since 2020
Robert Mcmahon
Chief Financial Officer, Senior Vice President · since 2025
Chad Winters
Chief Accounting Officer, Vice President - Finance · since 2024
Independent Director · since 2011
William Feehery
Independent Director · since 2012
Lead Independent Director · since 2025
Independent Director · since 2024
Thomas Hofmann
Independent Director · since 2007
Independent Director · since 2021
Deborah Keller Tanner
Independent Director · since 2017
Independent Director · since 2014
Independent Director · since 2022
Douglas Michels
Independent Director · since 2011
Independent Director · since 2025
Headquarters & legal address
C/O CORPORATION SERVICE COMPANY
530 HERMAN O. WEST DRIVE
EXTON, PA 19341
US
530 HERMAN O. WEST DRIVE
EXTON, PA 19341
US
Trading name
THE WEST COMPANY INCORPORATED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||